Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Charged multivesicular body protein 1B2, pseudogene (CHMP1B2P) is annotated in the human genome as a nonfunctional DNA sequence derived from a duplication or mutation of a parent gene, in this case resembling the CHMP1B gene. Pseudogenes like CHMP1B2P do not encode active proteins and are not considered drug targets, although emerging research suggests some pseudogenes may have regulatory functions in development or disease by affecting gene expression, chromatin structure, or RNA networks. However, there is currently no direct evidence or annotation of CHMP1B2P being functionally important or therapeutically actionable. CHMP1B2P is not a receptor, enzyme, transporter, transcription factor, or any other canonical therapeutic target; it is a pseudogene (a genomic relic generally lacking biological function). If you are seeking a therapeutic target, this entry is likely inappropriate or incorrect.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Charged multivesicular body protein 1B2, pseudogene (CHMP1B2P).